- Home
- KURA vs NAVI Comparison
KURA vs NAVI Comparison
Compare KURA & NAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KURA | NAVI |
|---|---|---|
| Founded | 2014 | 1973 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 841.6M | 760.4M |
| IPO Year | 2015 | 2014 |
Fundamental Metrics
Financial Performance| Metric | KURA | NAVI |
|---|---|---|
| Price | $10.86 | $9.17 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 11 | 6 |
| Target Price | ★ $25.56 | $10.00 |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 6.73% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.44 |
| Revenue | $67,482,000.00 | ★ $271,000,000.00 |
| Revenue This Year | $28.28 | $76.23 |
| Revenue Next Year | $106.37 | $15.73 |
| P/E Ratio | ★ N/A | $21.00 |
| Revenue Growth | ★ 25.24 | N/A |
| 52 Week Low | $6.95 | $7.33 |
| 52 Week High | $12.49 | $13.87 |
Technical Indicators
Market Signals| Indicator | KURA | NAVI |
|---|---|---|
| Relative Strength Index (RSI) | 62.15 | 57.46 |
| Support Level | $8.63 | $7.91 |
| Resistance Level | $11.40 | $9.68 |
| Average True Range (ATR) | 0.57 | 0.42 |
| MACD | 0.13 | 0.02 |
| Stochastic Oscillator | 84.34 | 76.05 |
Price Performance
Historical ComparisonAbout KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
About NAVI Navient Corporation
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in two segments: Federal Education Loans, and Consumer Lending. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.